Simple oral spray vaccine prevents UTIs for up to nine years: Research

Uromune, an oral spray vaccine, has shown significant efficacy in preventing recurrent urinary tract infections (UTIs) for up to nine years in over half of participants. A recent study led by clinicians at the Royal Berkshire Hospital demonstrated the vaccine's safety and efficacy, with around 54% of participants remaining UTI-free during the nine-year follow-up period. The vaccine's ease of administration and long-term benefits make it a potential game-changer in UTI prevention, reducing reliance on antibiotic treatments. With its availability in 26 countries, including the UK and Australia, Uromune offers hope for individuals prone to recurrent UTIs. Ongoing research aims to explore its effectiveness in different patient groups, promising further insights into its widespread application in clinical settings.

Reference:

EAU24 European Association of Urology Congress